Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy

Breast Cancer Clinical Trial

Official title:

A Pilot Study Comparing Acute Post-Radiation Hyperbaric Oxygen (HBO2) Versus Trental and Vitamin E for Breast Cancer Patients Who Have Recently Completed Radiation Therapy as Part of Their Treatment Course

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03916068
• Other study ID #: HBO001
• Status: Terminated
• Phase: Phase 2
• Start date: July 1, 2019
• Est. completion date: October 2, 2023

Study information

• Verified date: October 2023
• Source: Legacy Health System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to compare patients that receive hyperbaric oxygen or Trental and Vitamin E immediately after completion of radiation therapy to evaluate which treatment best reduces radiation fibrosis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: October 2, 2023
• Est. primary completion date: October 2, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• > 18 years of age
• Patient is currently undergoing treatment for breast cancer and is on one of two

pathways:

• Pathway 1 involves lumpectomy with radiation therapy, recurrence years later, mastectomy and tissue expander with further radiation therapy
• Pathway 2 involves mastectomy and tissue expander, 6 weeks of radiation therapy, and an implant in 6 months
• Undergone mastectomy with expander or implant reconstruction > 2 weeks before starting radiation therapy
• Completed chest wall irradiation in the past 3 days
• Willing to stop herbal medications as directed by provider
• Willing to stop daily use of supplemental vitamin E (Multivitamin with vitamin E component is acceptable, vitamin E cream is also acceptable)
• Willing to have photographs of chest area taken for research purposes only
• Therapeutic PT-INR for participants taking Coumadin
• If tissue expanders remain intact during radiation, plan for conversion to the final implants must occur > 4 months after completing radiation
• Willing to travel to a Legacy Health facility for study related visits
• Agree to attend study visits outside of standard of care visits, if needed
• Willing to engage in pre/post testing and survey/phone calls
• Willing to attend all 6 weeks of HBOT if randomized to that group

Exclusion Criteria:

• < 18 years of age
• Pregnant or lactating
• Have final implant placed < 2 weeks before start of radiation therapy
• Plan to place final impacts < 4 months from the completion of radiation therapy, if tissue expanders are intact during radiation therapy
• Have evidence of ongoing infection or implant exposure before start of radiation therapy
• Radiation completed more than 3 days prior to study start
• Unable to comply with protocol
• Unable to provide written informed consent
• Unwilling or unable to stop oral supplemental Vitamin E
• PT-INR outside of acceptable range for participants taking Coumadin
• Any delay in radiation treatment greater than 14 days
• Investigator does not believe study participation is in the best interest of the patient
• History of a seizure within the last 5 years

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Procedure:
• Hyperbaric Oxygen Therapy
Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.

Drug:
• Trental Pill
Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily

Dietary Supplement:
• Vitamin E
Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily

Locations

Country	Name	City	State
United States	Legacy Emanuel Medical Center	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Legacy Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in breast fibrosis using Bakers Grade Assessment	The Bakers Grade Assessment will be used to evaluate if lower incidence and severity of radiation fibrosis is observed in patients receiving post-operative hyperbaric oxygen treatment as compared to Trental and Vitamin E. The difference-from-baseline (DFB) score will be calculated to determine the incidence and severity of radiation fibrosis. Some patients may develop radiation fibrosis at a later time so the assessment will be done multiple throughout the three years to capture timing of fibrosis onset.	Administered at week 1, week 7, week 13, week 25, week 53, and week 157.
Secondary	Objective measurements of tissue pliability using a Tissue Compliance Meter		Obtained at week 1, week 7, week 13, week 25, week 53, and week 157.
Secondary	Patients' sense of well-being using SF-20 Quality of life survey.	Short Form 20 is a survey that patients complete to indicate their overall quality of life. The SF-20 is weighted and summed to provide easily interpretable scales for physical and mental health.	Administered at week 1, week 7, week 13, week 25, week 53, and week 157.
Secondary	Pain in radiated breasts using a Visual Analog Scale	Visual Analog Scale is a way for patients to assess their pain, on a scale of one to ten with ten being worst pain imaginable.	Administered at week 1, week 7, week 13, week 25, week 53, and week 157.
Secondary	Presence of delayed wound healing, surgical complications, implant revision or loss		Evaluated at week 1, week 7, week 13, week 25, week 53, and week 157.